AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1 at AGC Inc.’s Yokohama Technical Center.

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.

Earlier this week, San Diego startup Gallant announced $18 million in funding to bring the first FDA-approved ready-to-use stem cell therapy to veterinary medicine. If it passes regulatory muster ...

AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase ...

Cellares grows in NJ and globally with Smart Factories and key partnerships to advance scalable, cost-effective cell therapy manufacturing.

Current approved CAR T-cell therapy treatments rely on an ex vivo route, in which a patient’s T cells are removed, genetically engineered to target antigens, and put back into the patient.

Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions.

An off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results, according to a new study.

Zemcelpro provides an option for people with a hematologic malignancy who need a blood stem cell transplant but have no suitable donor.

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...